share_log

Jiangsu Huifeng Bio Agriculture (SZSE:002496) Shareholders Are up 20% This Past Week, but Still in the Red Over the Last Five Years

Jiangsu Huifeng Bio Agriculture (SZSE:002496) Shareholders Are up 20% This Past Week, but Still in the Red Over the Last Five Years

江蘇輝豐生物農業(SZSE:002496)股東上週上漲了20%,但在過去五年中仍處於虧損狀態
Simply Wall St ·  03/19 20:36

Jiangsu Huifeng Bio Agriculture Co., Ltd. (SZSE:002496) shareholders will doubtless be very grateful to see the share price up 52% in the last month. But if you look at the last five years the returns have not been good. After all, the share price is down 28% in that time, significantly under-performing the market.

江蘇匯豐生物農業有限公司(深圳證券交易所:002496)股東們無疑將非常感激地看到上個月股價上漲了52%。但是,如果你看看過去的五年,回報並不理想。畢竟,當時股價下跌了28%,表現大大低於市場。

While the stock has risen 20% in the past week but long term shareholders are still in the red, let's see what the fundamentals can tell us.

儘管該股在過去一週上漲了20%,但長期股東仍處於虧損狀態,但讓我們看看基本面能告訴我們什麼。

Because Jiangsu Huifeng Bio Agriculture made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

由於江蘇匯豐生物農業在過去十二個月中出現虧損,我們認爲至少目前市場可能更加關注收入和收入增長。無利可圖的公司的股東通常期望強勁的收入增長。一些公司願意推遲盈利以更快地增加收入,但在這種情況下,人們確實預計收入會有良好的增長。

Over half a decade Jiangsu Huifeng Bio Agriculture reduced its trailing twelve month revenue by 36% for each year. That puts it in an unattractive cohort, to put it mildly. On the face of it we'd posit the share price fall of 5% compound, over five years is well justified by the fundamental deterioration. We doubt many shareholders are delighted with this share price performance. Risk averse investors probably wouldn't like this one much.

在過去的五年中,江蘇匯豐生物農業將其過去十二個月的收入每年減少36%。客氣地說,這使它成爲一個沒有吸引力的群體。從表面上看,我們認爲股價在五年內複合下跌了5%,這完全是基本面惡化所證明的。我們懷疑許多股東對這種股價表現感到滿意。規避風險的投資者可能不會太喜歡這個。

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

公司的收入和收益(隨着時間的推移)如下圖所示(點擊查看確切數字)。

earnings-and-revenue-growth
SZSE:002496 Earnings and Revenue Growth March 20th 2024
SZSE: 002496 2024 年 3 月 20 日收益和收入增長

This free interactive report on Jiangsu Huifeng Bio Agriculture's balance sheet strength is a great place to start, if you want to investigate the stock further.

如果你想進一步調查該股,這份關於江蘇輝豐生物農業資產負債表實力的免費互動報告是一個很好的起點。

A Different Perspective

不同的視角

While the broader market lost about 9.5% in the twelve months, Jiangsu Huifeng Bio Agriculture shareholders did even worse, losing 21%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 5% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 1 warning sign we've spotted with Jiangsu Huifeng Bio Agriculture .

儘管整個市場在十二個月中下跌了約9.5%,但江蘇匯豐生物農業股東的表現甚至更糟,跌幅爲21%。話雖如此,在下跌的市場中,一些股票不可避免地會被超賣。關鍵是要密切關注基本發展。遺憾的是,去年的業績結束了糟糕的表現,股東在五年內每年面臨5%的總虧損。總的來說,長期股價疲軟可能是一個壞兆頭,儘管逆勢投資者可能希望研究該股以期出現轉機。儘管市場狀況可能對股價產生的不同影響值得考慮,但還有其他因素更爲重要。爲此,你應該注意我們在江蘇匯豐生物農業發現的1個警告信號。

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

如果你像我一樣,那麼你不會想錯過這份業內人士正在收購的成長型公司的免費名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論